Brain Tumor & Glioblastoma Clinical Trials in Northeast Ohio
With groundbreaking clinical trials, UH Seidman Cancer Center’s physicians have established many innovations in treating glioblastoma and other brain cancers in collaboration with the UH Neurological Institute’s Brain Tumor and Neuro-Oncology Center. Our patients have access to the most current clinical trials, treatments, and procedures unavailable at other facilities.
Interested in Participating in a Brain Tumor Study or Trial?
Learn more about participating in our research studies and clinical trials by browsing our actively recruiting studies & trials below.
You may also sign up online or call 1-800-641-2422 today.
Actively Recruiting Studies & Trials
Glioblastoma (GBM) AGILE Trial
A Major Step Toward Precision Medicine for Malignant Brain Tumors
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM Study
Recurrent GBM (RGBM) & LITT Trial
Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM).
As one of the best cancer hospitals in the country by U.S. News & World Report for over 20 consecutive years, UH Seidman Cancer Center is a member of the Adult Brain Tumor Consortium, one of 11 elite Brain Tumor Centers of Excellence, and is part of the National Cancer Institute (NCI)-designated Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine – one of an elite group of 51 comprehensive cancer hospitals nationwide. The Case Comprehensive Cancer Center has an “Exceptional” rating from the NCI, a rating only seven NCI-designated comprehensive cancer centers currently hold.
Can the Polio Virus Kill Brain Tumors?
UH one of 4 sites participating in Phase II clinical trial
Newly FDA-approved Imaging Agent That Makes Brain Tumors Glow Hot Pink
Distinguishes tumor from healthy tissue to improve tumor removal
Clinical Trial Investigates New Gene Therapy for Brain Tumors
UH Neurosurgeon Testing Novel Gene Therapy Treatment for Glioblastoma
New $2.7 million grant from the National Cancer Institute will help validate promising approach